We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Catalyst Pharmaceuticals Inc is a biotechnology business with stocks listed in the US. Catalyst Pharmaceuticals shares (CPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$5.76 – a decrease of 4.48% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$2.875 - US$6.6 |
|---|---|
| 50-day moving average | US$5.4691 |
| 200-day moving average | US$5.4002 |
| Target price | US$8.5 |
| PE ratio | 8.1818 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$0.704 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $5.76
| 1 week (2021-10-14) | -5.26% |
|---|---|
| 1 month (2021-09-24) | 13.39% |
| 3 months (2021-07-23) | 3.78% |
| 6 months (2021-04-23) | 23.34% |
| 1 year (2020-10-23) | 80.56% |
|---|---|
| 2 years (2019-10-24) | 6.27% |
| 3 years (2018-10-24) | 85.21% |
| 5 years (2016-10-24) | 376.03% |
Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Catalyst Pharmaceuticals shares trade at around 8x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$46.1 million (£0.0 million).
The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$126.9 million |
|---|---|
| Operating margin TTM | 36.22% |
| Gross profit TTM | US$87.1 million |
| Return on assets TTM | 16.87% |
| Return on equity TTM | 49.72% |
| Profit margin | 58.8% |
| Book value | 1.832 |
| Market capitalisation | US$593.2 million |
TTM: trailing 12 months
There are currently 4.7 million Catalyst Pharmaceuticals shares held short by investors – that's known as Catalyst Pharmaceuticals's "short interest". This figure is 9.2% down from 5.2 million last month.
There are a few different ways that this level of interest in shorting Catalyst Pharmaceuticals shares can be evaluated.
Catalyst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Catalyst Pharmaceuticals shares currently shorted divided by the average quantity of Catalyst Pharmaceuticals shares traded daily (recently around 884897.01492537). Catalyst Pharmaceuticals's SIR currently stands at 5.36. In other words for every 100,000 Catalyst Pharmaceuticals shares traded daily on the market, roughly 5360 shares are currently held short.
However Catalyst Pharmaceuticals's short interest can also be evaluated against the total number of Catalyst Pharmaceuticals shares, or, against the total number of tradable Catalyst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalyst Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Catalyst Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0496% of the tradable shares (for every 100,000 tradable Catalyst Pharmaceuticals shares, roughly 50 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Catalyst Pharmaceuticals.
Find out more about how you can short Catalyst Pharmaceuticals stock.
We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as US$2.875 up to US$6.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 1.3466. This would suggest that Catalyst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
